Syantra Q&A with Karen Matthews

Mar 02, 2022

“CPSA accreditation helps patients know that quality and safety are top priorities for medical and diagnostic facilities.”

The vast majority of medical decisions made by a physician for a patient are based on the results of diagnostic tests. These results impact patient care pathways, treatments and outcomes. It’s not surprising, then, that being accredited to offer a diagnostic test is a big deal. A very big deal.


Last year, when Syantra Inc. earned its College of Physicians and Surgeons of Alberta (CPSA) Lab Accreditation for its precision medicine breast cancer screening test, it was the culmination of years of research, focus and intent. It was also a nod to the guidance and support of Karen Matthews, who has helped to guide Syantra through the regulatory steps necessary to bring Syantra DX | Breast Cancer to market. Here’s what she had to say about her role, the CPSA accreditation and the importance of continuous improvement.

What is your role at Syantra?

My role as a Quality and Regulatory Affairs Consultant at Syantra is to help the team understand rules and regulations, develop processes and documents, and implement the various requirements needed in order to meet, or exceed, the many varied requirements for the different accrediting bodies, such as ISO 13485 and CPSA. 


For most regulatory bodies, the basis of their requirements is a strong, well-established, and well-controlled Quality Management System (QMS) that ensures the laboratory produces high-quality results, services or products, and demonstrates a commitment to quality. Being accredited by provincial and national accrediting bodies opens doors globally to be able to provide services all around the world.

What is the College of Physicians and Surgeons of Alberta?

The College of Physicians and Surgeons of Alberta (CPSA) is… responsible for the oversight of the practice of medicine in Alberta, including all diagnostic laboratory services. It’s a trusted voice in the Alberta healthcare system, which works collaboratively with the Minister of Health, the government and members of the public.


Alberta laboratories that perform and report diagnostic tests to guide patient care must be accredited by CPSA, which is responsible for writing facility accreditation standards and assessing these facilities. CPSA also encourages the development of a culture of continuous improvement, quality assurance and safety within these organizations. Accreditation helps patients know that quality and safety are top priorities for medical and diagnostic facilities.

Syantra’s lab is CPSA accredited. What does that mean for physicians and patients? 

It means that Syantra has satisfied all of the standards and requirements that are provided by the CPSA and has been designated as an “accredited laboratory”. This gives physicians and patients the assurance that the quality and safety of the results provided are meeting high quality and safety requirements.

How did Syantra achieve accreditation?

The CPSA has a set of general standards that apply to all laboratories, as well as a discipline-specific set of standards for each laboratory discipline…Syantra is assessed to the general standards as well as the molecular diagnostics and genetics standards.


CPSA conducts an on-site assessment in a peer-review process when a facility first opens, and then reassesses the facility on a four-year cycle… Facilities are also reassessed if the location moves, adds a new service, renovates or if a concern is brought forward to the CPSA.

How do CPSA accreditation criteria stack up against those of other provinces?

CPSA is part of the Western Canada Diagnostic Accreditation Alliance, so the standards are similar to those used in Saskatchewan and Manitoba under their own provincial College of Physicians and Surgeons. 


CPSA standards are very comprehensive. Their Diagnostic laboratory Standards are recognized as among the highest in the world by the International Society for Quality in Health Care External Evaluation Association (IEEA).

Are the standards around CPSA accreditation routinely audited? If so, how will Syantra ensure excellence in maintaining those standards?

Continued improvements, quality assurance and continued auditing of processes are all part of maintaining accreditation readiness for the laboratory. There are numerous systems in place from managing documents and records to safety and facility maintenance as outlined in the Quality Management System. There are processes in place for internal assessments and annual reviews of the QMS to continually identify Opportunities For Improvement (OFIs) in order to improve… The CPSA standards themselves undergo an annual review and periodic updates. Prior to an on-site accreditation, the updated versions are customized and provided to the facility ahead of the scheduled actual on-site visit.

Syantra press release graphic dated November 14, 2023
14 Nov, 2023
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
01 Nov, 2023
CALGARY, AB. - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DX™ Breast Cancer , announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. “Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape,” said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. “We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DX™ Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease.” “The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that’s exactly what Syantra’s liquid biopsy platform will become” states CEO of Syantra, Rob Lozuk, and adds, “I’m thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI-powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body’s immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DX™ Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024.” Within the precision biotech space, Syantra’s liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to bioMérieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific’s Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra’s scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning-based algorithms. Syantra’s blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DX™ Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DX™ Breast Cancer , is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DX™ Breast Cancer test will be available to women in Canada and the United States in early 2024.
Cara Campbell, breast cancer survivor, poses for a photo with her grandson, Rhett.
22 Aug, 2023
At age 29, Cara woke up with a small lump on her chest. Cara made sure to visit her doctor right away for a thorough breast exam and mammogram. Two weeks later, after an ultrasound and a biopsy, Cara was diagnosed with breast cancer.
Katie Smith-Parent, stage two hormone-positive breast cancer survivor,  smiles in her kitchen.
25 May, 2023
In her early 30s, Katie Smith-Parent noticed a lump on her breast. She was initially told by a doctor not to worry and that the lump would go away on its own. She trusted her instincts and after finding a new doctor, she was diagnosed with stage two hormone-positive breast cancer. Today, she is an advocate for early detection and oncofertility.
Syantra Press Release graphic dated April 18, 2023
18 Apr, 2023
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Olesya Kharenko stands in front of Syantra lab in lab coat.
08 Feb, 2023
The typical career journey for a scientist is fairly linear. But a lens focused on only one speciality can make it challenging to leverage the many ways these disciplines can crossover. Imagine the possibilities of a single scientist who brings expertise from more than three disciplines to research. Syantra found that in Olesya Kharenko, PhD.
Syantra press release dated January 18, 2023 announcing promotion of Carol Roesler to VP
16 Jan, 2023
Syantra Inc. announced today the promotion of Carol Roesler to Vice President, effective January 2023. Carol will maintain her current responsibilities in her new role, in addition to supporting Canadian business development for the Syantra DX™ Breast Cancer test.
Syantra DX Breast Cancer requisition with blood test tube
08 Nov, 2022
Syantra will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.
Syantra press release dated October 27, 2022 announcing appointment of Dr. Massimo Cristofanilli
27 Oct, 2022
Syantra appoints Dr. Massimo Cristofanilli, a world-renowned leader in the field of breast cancer, to its Scientific Advisory Board (SAB) effective Sept 1, 2022. Dr. Cristofanilli is a Professor of Medicine, Chief of Breast Medical Oncology and Associate Director of Precision Medicine at Weill-Cornell Medicine.
Jesslyn Davies, a 33-year-old woman battling breast cancer, smiling in her Calgary home
18 Oct, 2022
In November 2020, Jesslyn Davies, a 33-year-old registered nurse and mother of two young boys, noticed a small cyst on her breast. Soon after, she was diagnosed with Triple Negative Stage 2B breast cancer.
More Posts
Share by: